Skip to main content
HR 8662 116th Congress House Health Advisory bodies Congressional oversight Drug safety, medical device, and laboratory regulation Drug therapy Government information and archives Health care coverage and access Health care quality Health information and medical records Health programs administration and funding Health promotion and preventive care Medical research Medical tests and diagnostic methods Neurological disorders Public contracts and procurement Research administration and funding Research and development

Accelerating Access to Critical Therapies for ALS Act

Introduced: October 23, 2020 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 23, 2020
Referred to the House Committee on Energy and Commerce.
Oct 23, 2020
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Accelerating Access to Critical Therapies for ALS Act

This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.

The Department of Health and Human Services (HHS) shall award grants to eligible entities to support research on and facilitate access to investigational drugs that diagnose or treat ALS. The Food and Drug Administration shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other severely debilitating neurodegenerative diseases.

HHS shall also establish the Collaborative for Neurodegenerative Diseases, which shall support the development and regulatory approval of drugs that address ALS and other rare neurodegenerative diseases.

What's happening now October 23, 2020

Referred to the House Committee on Energy and Commerce.

 Related & companion bills 1
  • S 4867 Identical bill Accelerating Access to Critical Therapies for ALS Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 238
All 238 Democratic 98 Republican 69
D
Gottheimer, Josh
New Jersey · Dec 24, 2020
 D
Torres, Norma J.
California · Dec 21, 2020
 R
Curtis, John R.
Utah · Dec 18, 2020
 D
Escobar, Veronica
Texas · Dec 18, 2020
 R
Johnson, Mike
Louisiana · Dec 18, 2020
 D
Slotkin, Elissa
Michigan · Dec 18, 2020
Higgins, Brian
· Dec 17, 2020
 D
Sherman, Brad
California · Dec 17, 2020
 D
Courtney, Joe
Connecticut · Dec 15, 2020
 R
Estes, Ron
Kansas · Dec 15, 2020
 R
Graves, Sam
Missouri · Dec 15, 2020
 R
Huizenga, Bill
Michigan · Dec 15, 2020
 D
Kaptur, Marcy
Ohio · Dec 15, 2020
 D
Larson, John B.
Connecticut · Dec 15, 2020
 D
Lieu, Ted
California · Dec 15, 2020
Luetkemeyer, Blaine
· Dec 15, 2020
 D
Pappas, Chris
New Hampshire · Dec 15, 2020
 R
Scalise, Steve
Louisiana · Dec 15, 2020
 D
Smith, Adam
Washington · Dec 15, 2020
 R
Turner, Michael R.
Ohio · Dec 15, 2020
 D
Watson Coleman, Bonnie
New Jersey · Dec 15, 2020
 R
Balderson, Troy
Ohio · Dec 9, 2020
 D
Espaillat, Adriano
New York · Dec 9, 2020
 D
Jeffries, Hakeem S.
New York · Dec 9, 2020
 D
Thompson, Mike
California · Dec 9, 2020
Herrera Beutler, Jaime
· Dec 8, 2020
SERRANO, JOSE
· Dec 8, 2020
 R
Simpson, Michael K.
Idaho · Dec 8, 2020
 R
Wilson, Joe
South Carolina · Dec 8, 2020
 R
Aderholt, Robert B.
Alabama · Dec 7, 2020
 R
Bergman, Jack
Michigan · Dec 7, 2020
 D
DeSaulnier, Mark
California · Dec 7, 2020
 R
Gosar, Paul A.
Arizona · Dec 7, 2020
 D
Hayes, Jahana
Connecticut · Dec 7, 2020
Luria, Elaine
· Dec 7, 2020
 D
McBath, Lucy
Georgia · Dec 7, 2020
 D
Mfume, Kweisi
Maryland · Dec 7, 2020
Palazzo, Steven
· Dec 7, 2020
Richmond, Cedric
· Dec 7, 2020
 R
Smith, Christopher H.
New Jersey · Dec 7, 2020
 R
Smucker, Lloyd
Pennsylvania · Dec 7, 2020
Loebsack, David
· Dec 4, 2020
 R
McClintock, Tom
California · Dec 4, 2020
Sarbanes, John
· Dec 4, 2020
 D
Aguilar, Pete
California · Dec 3, 2020
Keller, Fred
· Dec 3, 2020
 D
Matsui, Doris O.
California · Dec 3, 2020
 R
Meuser, Daniel
Pennsylvania · Dec 3, 2020
Brown, Anthony
· Dec 2, 2020
 D
Brownley, Julia
California · Dec 2, 2020
Page 1 of 5 Next
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 8662: Accelerating Access to Critical Therapies for ALS Act. 116th Congress. Open America. https://openamerica.io/bill/116-HR-8662/
MLA
"H.R. 8662: Accelerating Access to Critical Therapies for ALS Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-8662/.
Bluebook (legal)
H.R. 8662, 116th Cong. (2026), https://openamerica.io/bill/116-HR-8662/.
Markdown link
[H.R. 8662: Accelerating Access to Critical Therapies for ALS Act](https://openamerica.io/bill/116-HR-8662/)
Report a problem